REPLY
27.7.2021 09:32:10 CEST | Business Wire | Press release
With the project “easyDream”, team Watermelon won the 2021 edition of the Creative Challenge, the largest team-based competition in Europe for students and young creatives and part of the Reply Challenges program.
Launched last May 21st with the online qualification marathon (running 48h), the challenge gathered over 12,000 creative talents (+94% vs. 2020 edition) from 82 countries around the World to focus their creative efforts on nine categories: "Brand Activation", "Brand Experience", "Employer Branding", "Employee Engagement", "Digital Customer Experience", "Digital Gamification", "Fan-base activation", "Innovation Design" and "Social Media".
Spread across over 1,900 teams (+90% vs. 2020 edition), the young talents - with an average age between 14 and 24 - put their skills and personalities into the development of a creative concept based on a real brief created by Reply in collaboration with the Brand Partners of the initiative: AC Milan, Ducati, easyJet, Miele, Mondelez International, Pamela Reif, Sky, Telekom and Tuc,
Nine finalist teams, Jovenhub (for the category Brand Activation powered by Miele), Actontown (for the category Brand Experience powered by Tuc), Creative minds (for the category Employer Branding powered by Sky), Kings & Castles (for the category Employee Engagement powered by Mondelez International), Watermelon (for the category Digital Customer Experience powered by easyJet), Power Up (for the category Digital Gamification powered by Telekom), Cookies accepted (for the category Fan-base Activation powered by AC Milan), Replikate (for the category Innovation Design powered by Pamela Reif) and Creathics (for the category Social Media powered by Ducati), progressed to the final round that took place on July 1st , during which they had the opportunity to exhibit their concepts to an exceptional jury composed of the Art and Creative Directors of Reply agencies (Avvio Reply, Bitmama Reply, Open Reply, Triplesense Reply, WM Reply and Xister Reply) and some of the most renowned marketing and communication professionals of the Brand Partners of the initiative who gave tips and feedbacks on the teams’ work.
Live streamed on Facebook and YouTube, the presentations were judged on a combination of elements and skills as the quality of the presentation, the adherence to the briefs assigned, the originality of the project and the highly quality materials produced. Team Watermelon finished top of the podium, presenting an idea in the Digital Customer Experience category powered by easyJet that leverages on the users’ emotional expectations to choose the next holiday destination.
Team Watermelon, composed by Fedele Cavaliere (22 years old), Andrea De Bernardi (22 years old), Elisa Manzoni (23 years old) and Elio Raineri (23 years old), are all students of Digital and Interaction Design at the Politecnico of Milan University. The team commented the victory: “During the two days of challenge, we had a great time together, answering to a real brief, created by a real and prestigious brand. The possibility to free our creativity has allowed us to have fun and explore new concepts in many ways without constraints, leading our minds to the final result. Despite the short time, we had the chance to create an idea, capable of being shared with others and presented to an international jury, competing with other amazing teams.”
“Watermelon didn’t simply meet the brief – they exceeded it at every opportunity. Their designs employed the perfect balance of creativity, research, and UX design methodology – but on top of that, they produced stunning interactive prototypes, marketing ideas, and a thoroughly entertaining pitch video. What the team managed to pull off in a single weekend is nothing short of amazing!“ commented the jury of the "Digital Customer Experience" cateogy composed by Karina Berzinska, Digital Product Manager easyJet, Alex Black, Lead Product Owner easyJet Holidays and Alex Reekie, Senior Manager WM Reply.
The Creative Challenge is part of the Reply Challenges 2021 competition series organized by Reply for young students, talents and technology enthusiasts to promote the culture of coding and stimulate digital innovation in the fields of creativity, cybersecurity and finance.
To find out more about the Creative Challenge 2021 please visit challenges.reply.com .
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005073/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom